Non-AIDS-related Kaposi’s sarcoma:A single-institution experience  

Non-AIDS-related Kaposi’s sarcoma:A single-institution experience

在线阅读下载全文

作  者:Pasquale Rescigno Rossella Di Trolio Carlo Buonerba Gaia De Fata Piera Federico Davide Bosso Antonella Virtuoso Michela Izzo Tania Policastro Luca Vaccaro Gianfranco Cimmino Francesco Perri Elide Matano Mario Delfino Sabino De Placido Giovannella Palmieri Giuseppe Di Lorenzo 

机构地区:[1]Genitourinary Cancer Section and Rare-Cancer Center,Medical Oncology Division,University Federico II,80131 Napoli,Italy [2]Department of Dermatology,University Federico II of Naples,80131 Napoli,Italy

出  处:《World Journal of Clinical Oncology》2013年第2期52-57,共6页世界临床肿瘤学杂志(英文版)

摘  要:AIM:To evaluate the outcomes and potential prognostic factors in patients with non-acquired immunodeficiency syndrome(AIDS)-related Kaposi’s sarcoma(KS).METHODS:Patients with histologically proven non-AIDS-related KS treated with systemic chemotherapy were included in this retrospective analysis.In some cases,the human herpes virus 8 status was assessed by immunohistochemistry.The patients were staged according to the Mediterranean KS staging system.A multivariable model was constructed using a forward stepwise selection procedure.A P value<0.05 was considered statistically significant,and all tests were two-sided.RESULTS:Thirty-two cases were included in this analysis.The average age at diagnosis was 70 years,with a male/female ratio of approximately 2:1.Eighty-four percent of the cases had classic KS.All patients received systemic chemotherapy containing one of the following agents:vinca alkaloid,taxane,and pegylated liposomal doxorubicin.Ten patients(31.5%)experienced a partial response,and a complete response was achieved in four patients(12.4%)and stable disease in sixteen cases(50%).Two patients(6.2%)were refractory to the systemic treatment.The median progression-free survival(PFS)was 11.7 mo,whereas the median overall survival was 28.5 mo.At multivariate analysis,the presence of nodular lesions(vs macular lesions only)was significantly related to a lower PFS(hazard ratio:3.09;95%CI:1.18-8.13,P=0.0133).CONCLUSION:Non-AIDS-related KS appears mostly limited to the skin and is well-responsive to systemic therapies.Our data show that nodular lesions may be associated with a shorter PFS in patients receiving chemotherapy.AIM:To evaluate the outcomes and potential prognostic factors in patients with non-acquired immunodeficiency syndrome(AIDS)-related Kaposi’s sarcoma(KS).METHODS:Patients with histologically proven nonAIDS-related KS treated with systemic chemotherapy were included in this retrospective analysis.In some cases,the human herpes virus 8 status was assessed by immunohistochemistry.The patients were staged according to the Mediterranean KS staging system.Amultivariable model was constructed using a forward stepwise selection procedure.A P value < 0.05 was considered statistically significant,and all tests were two-sided.RESULTS:Thirty-two cases were included in this analysis.The average age at diagnosis was 70 years,with a male/female ratio of approximately 2:1.Eighty-four percent of the cases had classic KS.All patients received systemic chemotherapy containing one of the following agents:vinca alkaloid,taxane,and pegylated liposomal doxorubicin.Ten patients(31.5%) experienced a partial response,and a complete response was achieved in four patients(12.4%) and stable disease in sixteen cases(50%).Two patients(6.2%) were refractory to the systemic treatment.The median progression-free survival(PFS) was 11.7 mo,whereas the median overall survival was 28.5 mo.At multivariate analysis,the presence of nodular lesions(vs macular lesions only) was significantly related to a lower PFS(hazard ratio:3.09;95%CI:1.18-8.13,P = 0.0133).CONCLUSION:Non-AIDS-related KS appears mostly limited to the skin and is well-responsive to systemic therapies.Our data show that nodular lesions may be associated with a shorter PFS in patients receiving chemotherapy.

关 键 词:Kaposi’s SARCOMA Human HERPES virus 8 PACLITAXEL Pegylated LIPOSOMAL DOXORUBICIN VINBLASTINE 

分 类 号:R512.91[医药卫生—内科学] R752.9[医药卫生—临床医学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象